Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Gen T-cell Engaging Multispecific Antibodies June 23, 2026
Positive Updated Results from RAMP 205 of Avutometinib, Defactinib and SOC chemo in 1L Metastatic Pancreatic Cancer Announced June 23, 2026
First Patient Dosed in TARGET-D 201 Ph 2 Registration-Directed Trial of VS-7375 for KRAS G12D-Mutated Metastatic Pancreatic Cancer June 23, 2026
Multiple Complete Responses Reported After ELI-002 7P Treatment and Subsequent Therapy with Checkpoint Inhibition in Metastatic mKRAS Pancreatic Cancer June 23, 2026
Ph 3 STELLAR-303 Trial of Zanzalintinib + Tecentriq in Metastatic CRC Patients didn’t meet the dual primary endpoint of OS improvement in the liver mets patients June 23, 2026
Parabilis Medicines Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares June 17, 2026
Update Provided on Safety Profile of LYL273 in R/R Metastatic CRC and Ph 1 Trial Amended to Ph 1/2 Expansion June 17, 2026
FAILED TRIAL: Ph 2 AMPLIFY-7P trial did not meet the pre-specified primary endpoint of DFS in the ITT adjuvant pancreatic cancer population June 17, 2026
FDA accepted supplemental BLA filing for adjuvant Tecentriq and Tecentriq Hybreza in combination with chemo in stage III dMMR or MSI-H colon cancer and granted Priority Review; PDUFA: 9 October 2026 June 17, 2026
Serplulimab Approved by NMPA for Perioperative Gastric Cancer with tumour PD-L1 expression CPS ≥ 5, followed by adjuvant monotherapy June 17, 2026
IDEAYA Biosciences Announces Clinical Collaboration with Roche in MTAP-Deleted RAS-Mutant Pancreatic Cancer June 10, 2026
Positive Mid-Year Interim Clinical Progress Reported from Ph 2 Study of Ampligen® (rintatolimod) + Imfinzi for the Treatment of Pancreatic Cancer June 10, 2026
IBI343 (arcotatug tavatecan) Met Primary Endpoint in Ph 3 Study in Advanced Refractory Gastric Cancer and NDA Accepted by China NMPA June 10, 2026
FDA Orphan Drug Designation Granted to Oxaliplatin for the Treatment of Pancreatic Cancer June 2, 2026
FDA Accepts NDA with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with GIST June 2, 2026
CREATE Medicines Announces $122 Million Series B Financing to Advance In Vivo CAR Pipeline May 21, 2026
